Table 5 Summary of Results for Studies I, II, and III (combined results for process replicates a, b, c) for each peptide across sites for inter-site CV, intra-site CV, linear slope and % recovery.
Signature Peptide | Study I | Study II | Study IIIa | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Inter- site CV | Intra- site CV | Linear Slope | % Recov. | Inter- site CV | Intra- site CV | Linear Slope | % Recov. | Inter- site CV | Intra- site CV | Linear Slope | % Recov. |
APR-AGL | 9.20% | 3.9-11.2% | 1.157 | 114.5 | 13.10% | 2.0-7.8% | 0.575 | 57.5 | 13.70% | 7.3-45.2% | 0.738 | 79.4 |
CRP-ESD | 5.90% | 2.2-5.9% | 1.124 | 118.4 | 10.50% | 3.1-8.4% | 0.573 | 61.4 | 16.70% | 8.5-18.1% | 0.439 | 48.9 |
CRP-GYS | 5.40% | 1.4-10.2% | 1.324 | 140.5 | 5.60% | 1.2-6.4% | 0.546 | 56 | 18.50% | 6.6-35.0% | 0.159 | 18.5 |
HRP-SSD | 14.10% | 4.0-8.9% | 1.198 | 120.4 | 5.50% | 4.6-7.3% | 0.794 | 82.3 | 21.90% | 8.4-21.4% | 0.43 | 45.7 |
LEP-IND | 12.50% | 2.9-10.3% | 1.163 | 119.1 | 29.50% | 2.6-15.3% | 0.152 | 14.9 | 50.40% | 11.7-54.9% | 0.242 | 25.6 |
MBP-HGF | 4.30% | 1.7-6.3% | 1.161 | 118.6 | 9.30% | 1.5-7.8% | 0.758 | 77.3 | 21.80% | 7.4-32.8% | 0.238 | 23.8 |
MBP-YLA | 5.10% | 2.1-9.3% | 1.275 | 130.3 | 4.10% | 1.5-14.1% | 0.806 | 83.8 | N/A | N/A% | N/A | > 1.0 |
MYO-LFT | 4.90% | 1.6-5.7% | 1.518 | 154.4 | 3.80% | 2.0-6.3% | 1.012 | 101.3 | 23.10% | 8.9-21.6% | 0.504 | 60.4 |
PSA-IVG | 6.90% | 1.3-14.7% | 1.658 | 165.4 | 5.50% | 2.0-11.2% | 0.848 | 81.9 | 17.20% | 7.6-13.7% | 0.587 | 58 |
PSA-LSE | 8.90% | 1.2-6.9% | 1.098 | 111.4 | 5.30% | 2.0-4.6% | 1.524 | 151.3 | 10.30% | 7.6-13.7% | 0.918 | 92.7 |